Equities Analysts Issue Forecasts for CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – HC Wainwright increased their FY2025 EPS estimates for shares of Celldex Therapeutics in a report issued on Wednesday, November 20th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($2.99) per share for the year, up from their previous forecast of ($3.02). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.45) per share.

CLDX has been the topic of several other reports. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Finally, Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $27.02 on Friday. The stock has a market cap of $1.79 billion, a PE ratio of -10.51 and a beta of 1.60. The firm has a fifty day moving average price of $30.21 and a 200 day moving average price of $34.92. Celldex Therapeutics has a 1 year low of $22.93 and a 1 year high of $53.18.

Institutional Trading of Celldex Therapeutics

Large investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $76,000. KBC Group NV lifted its holdings in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares during the period. Ameritas Investment Partners Inc. increased its stake in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares during the period.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 3.80% of the stock is owned by insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.